SuperworthInmune Bio INMB
- Market cap
- $40.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Inmune Bio's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $43K−56% | $28K−71% | $14K−63% | $0 | $0 | $0 | $50K+257% | $0 | $0 | $0 | n/a | n/a | |
| R&D | $6M+16% | $6M+76% | $8.7M+110% | $7.1M+70% | $10.1M+68% | $7.4M+22% | $7.6M−12% | $5.8M−18% | $4.9M−52% | $2.3M−68% | $3.6M−52% | −$803K |
| SG&A | $2.6M+9% | $2.4M+3% | $2.3M+0% | $2.8M+22% | $2.2M−14% | $2.1M−12% | $2.3M−1% | $2.3M−20% | $2.5M+15% | $3.1M+49% | $2.2M−6% | $2.3M+1% |
| −$8.5M+15% | −$8.4M+49% | −$11M+72% | −$9.9M+54% | −$12.3M+44% | −$9.5M+13% | −$9.9M−10% | −$24.6M+149% | −$7.4M−40% | −$5.5M−42% | −$5.8M−41% | −$1.5M−94% | |
| Interest expense | $568K−100% | $467K | $357K−42% | $250K−60% | $145M+25428% | −$751.2M | $0 | $250K+0% | n/a | n/a | n/a | n/a |
| Net income | −$8.6M+11% | −$8.4M+44% | −$11M+69% | −$9.7M+50% | −$12.1M+41% | −$9.2M+10% | −$9.7M−12% | −$24.5M+151% | −$6.5M−47% | −$5.3M−43% | −$5.4M−45% | −$1.3M−95% |
| −$0.48+12% | −$0.47+42% | −$0.61+69% | −$0.50+39% | −$0.60+25% | −$0.41−13% | −$0.43−30% | −$1.05+110% | −$0.24−60% | −$0.20−51% | −$0.20−54% | −$0.05−95% | |
| 18M+0% | 18M+0% | 18M+0% | 19.3M+8% | 20.2M+12% | 22.2M+23% | 22.5M+25% | 23.3M+21% | 26.6M+32% | 26.6M+20% | 26.6M+18% | 26.7M+15% |
EPS, diluted: 16 periods, Q4 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 8 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Inmune Bio's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| INMBInmune Bio | $40.5M | n/m | n/a | n/m | n/m | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $83.3M | 12.8× | 18.1× | 1.4× | +7% | 6.8% |
More on Inmune Bio
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .